Lumen Technologies Inc (LUMN) Stock Price Today
Aura AI Summary
Key Stats
- $4.70BMarket Cap
- 12,493,748Volume
- MediaSector
- $11.8352W High
- $4.4652W Low
- 40 DaysTypical Hold Time
- $16.32BEnterprise Value
- -Div Yield
- -Trading Activity
Track Lumen Technologies Inc (LUMN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Lumen Technologies Inc has traded between a low of $4.46 and a high of $11.83, highlighting its annual price range. Buy and sell Lumen Technologies Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Most Recent News
Buckreef drives revenue to self-fund TRX Gold expansion amid strong gold market outlook.
TRX Gold Corporation is leveraging revenue from its Buckreef project to self-fund its expansion plans, reducing reliance on external financing. The gold market remains supportive with strong price forecasts for 2027 despite recent pullbacks. While th...

Trump administration launches new fraud-reporting commission program and reports progress on missing children and crime reduction.
In Week 92 of President Trump's second term, the administration introduced a 1% commission program rewarding Americans for reporting government fraud. They have located many missing unaccompanied alien children from previous years and reported signif...

Protagonist Therapeutics shifts to royalty model with FDA approvals and $300M buyback plan
Protagonist Therapeutics has transformed into a royalty-driven company with two FDA-approved drugs and strong cash reserves. The company secured lucrative royalties and milestones from partners Takeda and J&J, reducing its operational risks while mai...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.